| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Efruxifermin in patients with metabolic dysfunction-associated steatohepatitis: A GRADE-assessed systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Umama Alam, Shree Rath, Muhammad Ansab, Aamna Kashif, Furqan Ahmad Sethi, Hafiza Tooba Siddiqui, Zarar Ahmad Khan Afridi, Muhammad Burhan, Muhammad Abdullah Ali, Abdul Moiz, Zaryab Bacha, Ahmad Khan, Raheel Ahmed, Monsurah Bisola Alatise and Kamil Ahmad Kamil |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kamil Ahmad Kamil, Chief Physician, Consultant, MD, Department of Internal Medicine, Mirwais Regional Hospital, Shahre-Naw, Kandahar 3801, Afghanistan. drkamilahmad1@gmail.com |
| Key Words |
Efruxifermin; Metabolic-associated steatohepatitis; Metabolic dysfunction-associated steatotic liver disease; Liver fibrosis; Cholesterol; Adverse events; Patient outcomes |
| Core Tip |
This Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-assessed systematic review and meta-analysis of randomized controlled trials evaluates the efficacy and safety of efruxifermin, a long-acting fibroblast growth factor 21 analogue, in patients with compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis. Efruxifermin demonstrated significant improvements in liver fibrosis, MASH resolution, and metabolic parameters, with a tolerable safety profile. These findings highlight efruxifermin’s potential as a novel therapeutic option for compensated MASH cirrhosis, addressing a critical unmet need in this population. |
| Publish Date |
2026-03-26 09:22 |
| Citation |
Alam U, Rath S, Ansab M, Kashif A, Sethi FA, Siddiqui HT, Afridi ZAK, Burhan M, Ali MA, Moiz A, Bacha Z, Khan A, Ahmed R, Alatise MB, Kamil KA. Efruxifermin in patients with metabolic dysfunction-associated steatohepatitis: A GRADE-assessed systematic review and meta-analysis. World J Hepatol 2026; 18(3): 115411 |
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i3/115411.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v18.i3.115411 |
